Effects of Physical Activity Adequacy Mindsets on Health and Wellbeing
NCT03939572, Not applicable, Completed, Stanford University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Physical Activity Adequacy Mindsets on Health and Wellbeing | ClinicalTrials.gov |
| NCT number | NCT03939572 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 164 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Stanford University | ClinicalTrials.gov |
| Conditions | Activity Adequacy Mindsets | ClinicalTrials.gov |
| Interventions | Accurate step count feedback, Deflated step count feedback, Inflated step count feedback, Accurate feedback + mindset intervention | ClinicalTrials.gov |
| First posted | 2019-05-07 | ClinicalTrials.gov |
| Last updated | 2020-01-30 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Perceived Amount of Exercise Over 5 Weeks | 5 weeks: measured at baseline (onboarding session), in daily and weekly surveys, and at end of study (offboarding session) | Perceived Amount of Exercise (manipulation check), measured via 1-item self-report in all surveys. The full item is "Overall, how much exercise did you get today?", range 1 (None at all) - 5 (A great deal), with high values considered a better outcome. | ClinicalTrials.gov |
| Primary | Change in Activity Adequacy Mindset Over 5 Weeks | 5 weeks: measured at baseline (onboarding session), in weekly surveys, and at end of study (offboarding session) | Activity Adequacy Mindset (key mediator) measured via self-report in onboarding/ offboarding surveys (7 items) and weekly surveys (shortened, 5 items). This scale ranges from 1 - 7, with higher values representing better outcomes. The items will be combined in a composite score by averaging. | ClinicalTrials.gov |
| Primary | Change in Physical Health Over 5 Weeks | 5 weeks: measured at baseline (onboarding session) and end of study (offboarding session); except average daily heart rate, which is based on Apple Watch HR recordings measured approx. every 20 minutes when participant is wearing watch during the 5 weeks | Physical Health measures are BMI (calculated from self-reported height and weight measured in lab, BMI = kg/m\^2); Body fat percentage (measured on lab scale); Resting systolic and diastolic blood pressure (measured in lab); Resting heart rate (HR) (measured in lab); Average daily heart rate (measured by Apple Watch heart rate sensor); VO2max, approximated through the Canadian Home Fitness Test (based on post-exercise HR measured in lab); Perceived general health (measured via 1-item self-report); Perceived fitness (measured via 1-item self-report); Physical function and pain (measured via PROMIS-29 Profile v2.0 questionnaire). All measures will be factor analyzed and combined into a summary score (average of standardized scores weighted by variables' factor loading), provided factor analysis shows that they load onto one factor (i.e., rotated factor loadings of \>= \|0.4\|). Measures will also be analyzed separately for exploratory purposes. | ClinicalTrials.gov |
| Primary | Change in Mental Health Over 5 Weeks | 5 weeks: measured at baseline (onboarding session) and end of study (offboarding session) | Anxiety, depressive symptoms, ability to participate in social roles and activities, sleep disturbance, fatigue (measured via PROMIS (Patient-Reported Outcomes Measurement Information System)-29 Profile v2.0 questionnaire), and stress (measured via Perceived Stress Scale, PSS). Each PROMIS subscale ranges from 1-5, with higher values representing better outcomes. Items will be averaged into subscale composite scores. The PSS ranges from 1-5, with higher values representing worse outcomes. PSS items will be averaged into a composite score. All measures will be factor analyzed and combined into a summary score (average of standardized scores weighted by variables' factor loading), provided factor analysis shows that they load onto one factor (i.e., rotated factor loadings of \>= \|0.4\|). Measures will also be analyzed separately for exploratory purposes. | ClinicalTrials.gov |
| Primary | Change in Cognitive Function Over 5 Weeks | 5 weeks: measured at baseline (onboarding session) and end of study (offboarding session) | Stroop task performance | ClinicalTrials.gov |
| Secondary | Change in Affect Over 5 Weeks | 5 weeks: measured at baseline (onboarding session), in daily and weekly surveys, and at end of study (offboarding session) | Measured via self-report (Affect Valuation Index, AVI, and 2 items measuring stress/ anxiety). AVI items range from 1-5, with higher scores indicating higher frequency of any given emotion. Items will be averaged into 8 subscale composite scores according to the AVI protocol by averaging. Items measuring stress/ anxiety range from 1-5 with higher scores representing worse outcomes. All measures will be factor analyzed and combined into a summary score (average of standardized scores weighted by variables' factor loading), provided factor analysis shows that they load onto one factor (i.e., rotated factor loadings of \>= \|0.4\|). Measures will also be analyzed separately for exploratory purposes. | ClinicalTrials.gov |
| Secondary | Change in Self-Efficacy for Exercise Over 5 Weeks | 5 weeks: measured at baseline (onboarding session), in weekly surveys, and at end of study (offboarding session) | Measured via self-report (Self-Efficacy for Exercise scale). Items range from 1-5, with higher values representing better outcomes. Items will be averaged into a composite scale. | ClinicalTrials.gov |
| Secondary | Change in Motivation for exercise and health promotion Over 5 Weeks | 5 weeks: measured at baseline (onboarding session), in weekly surveys, and at end of study (offboarding session) | Measured via self-report (2 items measuring exercise motivation and health promotion motivation). Items range from 1-5, with higher values representing better outcomes. Items will be averaged into a composite scale. | ClinicalTrials.gov |
| Secondary | Change in Physical Activity Behavior Over 5 Weeks | 5 weeks: Step count measured by Apple Watch every ~ 15 min when participant is wearing watch during the 5 weeks; IPAQ and custom physical activity measure assessed in onboarding/ offboarding sessions, and the latter also in weekly surveys | Physical activity is measured via daily step count tracked by Apple Watch, and via self-report (IPAQ, and a measure adapted from NHANES for this study). All measures will be factor analyzed and combined into a summary score (average of standardized scores weighted by variables' factor loading), provided factor analysis shows that they load onto one factor (i.e., rotated factor loadings of \>= \|0.4\|). Measures will also be analyzed separately for exploratory purposes. | ClinicalTrials.gov |
| Secondary | Change in Other Health Behaviors (diet, sleep, drinking, smoking) Over 5 Weeks | 5 weeks: measured at baseline (onboarding session), in weekly surveys, and at end of study (offboarding session) | Measured via self-report (9 items). All measures will be factor analyzed and combined into a summary score (average of standardized scores weighted by variables' factor loading), provided factor analysis shows that they load onto one factor (i.e., rotated factor loadings of \>= \|0.4\|). Measures will also be analyzed separately for exploratory purposes. | ClinicalTrials.gov |
| Secondary | Change in Process Mindset Over 5 Weeks | 5 weeks: measured at baseline (onboarding session), in one of the weekly surveys, and at end of study (offboarding session) | Exercise process mindset and Health process mindset are measured via self-report (7 items per scale). Items range from 1-4, with higher values representing better outcomes. Items will be averaged into two composite scores (General Process Mindset and Exercise Process Mindset). If items from both subscales have sufficient reliability (Cronbach's alpha \> 0.7), they will be averaged into one composite scale. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 36696172 | DERIVED | PubMed |
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| DP2AT009511 | Harnessing Mindset in 21st Century Healthcare | CRUM, ALIA | STANFORD UNIVERSITY | NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH | 2016 | NIH RePORTER |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)